Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $63.8 million.

  • Ovid Therapeutics' Liabilities and Shareholders Equity fell 3780.27% to $63.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $315.1 million, marking a year-over-year decrease of 3652.19%. This contributed to the annual value of $92.2 million for FY2024, which is 3600.71% down from last year.
  • As of Q3 2025, Ovid Therapeutics' Liabilities and Shareholders Equity stood at $63.8 million, which was down 3780.27% from $77.4 million recorded in Q2 2025.
  • Ovid Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $237.5 million for Q1 2021, and its period low was $63.8 million during Q3 2025.
  • Its 5-year average for Liabilities and Shareholders Equity is $145.4 million, with a median of $143.4 million in 2023.
  • As far as peak fluctuations go, Ovid Therapeutics' Liabilities and Shareholders Equity surged by 38064.79% in 2021, and later crashed by 3795.9% in 2025.
  • Ovid Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $194.5 million in 2021, then fell by 20.19% to $155.3 million in 2022, then fell by 7.24% to $144.0 million in 2023, then crashed by 36.01% to $92.2 million in 2024, then crashed by 30.73% to $63.8 million in 2025.
  • Its Liabilities and Shareholders Equity was $63.8 million in Q3 2025, compared to $77.4 million in Q2 2025 and $81.7 million in Q1 2025.